Clene to Present at Upcoming October Conferences
Clene Inc. (Nasdaq: CLNN), a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases like ALS and MS, has announced its participation in two upcoming investor conferences in October 2024.
The company will attend the 2024 Maxim Healthcare Virtual Summit from October 15-17, with a fireside presentation scheduled for October 15 at 2:30 p.m. E.T. Clene will also participate in The ThinkEquity Conference 2024 on October 30 in New York City, presenting at 3:30 p.m. E.T.
Both events will feature presentations and one-on-one meetings. For the Maxim Healthcare Virtual Summit, interested parties can sign up to become M-Vest members. The ThinkEquity Conference presentation will be accessible via webcast.
Clene Inc. (Nasdaq: CLNN), una società biofarmaceutica in fase clinica focalizzata sul miglioramento della salute mitocondriale e sulla protezione della funzione neuronale per trattare malattie neurologiche come la SLA e la SM, ha annunciato la sua partecipazione a due prossimi conferenze per investitori nell'ottobre 2024.
La società parteciperà al 2024 Maxim Healthcare Virtual Summit dal 15 al 17 ottobre, con una presentazione prevista per il 15 ottobre alle 14:30 E.T. Clene parteciperà anche a The ThinkEquity Conference 2024 il 30 ottobre a New York, presentando alle 15:30 E.T.
Entrambi gli eventi presenteranno relazioni e incontri individuali. Per il Maxim Healthcare Virtual Summit, le parti interessate possono iscriversi per diventare membri M-Vest. La presentazione della ThinkEquity Conference sarà accessibile tramite webcast.
Clene Inc. (Nasdaq: CLNN), una empresa biofarmacéutica en fase clínica centrada en mejorar la salud mitocondrial y proteger la función neuronal para tratar enfermedades neurológicas como la ELA y la EM, ha anunciado su participación en dos próximas conferencias de inversores en octubre de 2024.
La empresa asistirá al 2024 Maxim Healthcare Virtual Summit del 15 al 17 de octubre, con una presentación programada para el 15 de octubre a las 2:30 p.m. E.T. Clene también participará en La Conferencia ThinkEquity 2024 el 30 de octubre en Nueva York, presentando a las 3:30 p.m. E.T.
Ambos eventos incluirán presentaciones y reuniones uno a uno. Para el Maxim Healthcare Virtual Summit, las partes interesadas pueden inscribirse para convertirse en miembros de M-Vest. La presentación de la Conferencia ThinkEquity estará disponible a través de webcast.
Clene Inc. (Nasdaq: CLNN), 신경퇴행성 질환인 ALS 및 MS 치료를 위한 미토콘드리아 건강 개선 및 신경 기능 보호에 집중하는 임상 단계의 생명공학 회사가 2024년 10월 두 개의 투자자 회의에 참석한다고 발표했습니다.
회사는 10월 15일부터 17일까지 열리는 2024 Maxim Healthcare Virtual Summit에 참석하며, 10월 15일 오후 2시 30분 E.T.에 예정된 캠프파이어 프레젠테이션을 진행합니다. Clene은 또한 10월 30일 뉴욕에서 열리는 The ThinkEquity Conference 2024에 참여하여 오후 3시 30분 E.T.에 발표할 예정입니다.
두 이벤트 모두 발표와 일대일 미팅을 포함합니다. Maxim Healthcare Virtual Summit의 경우 관심 있는 당사자는 M-Vest 회원으로 가입할 수 있습니다. ThinkEquity Conference 발표는 웹캐스트를 통해 접근할 수 있습니다.
Clene Inc. (Nasdaq: CLNN), une entreprise bio-pharmaceutique en phase clinique axée sur l'amélioration de la santé mitochondriale et la protection de la fonction neuronale pour traiter des maladies neurologiques telles que la SLA et la SEP, a annoncé sa participation à deux conférences pour investisseurs à venir en octobre 2024.
L'entreprise assistera au 2024 Maxim Healthcare Virtual Summit du 15 au 17 octobre, avec une présentation prévue pour le 15 octobre à 14h30 E.T. Clene participera également à The ThinkEquity Conference 2024 le 30 octobre à New York, où elle présentera à 15h30 E.T.
Les deux événements comporteront des présentations et des réunions individuelles. Pour le Maxim Healthcare Virtual Summit, les parties intéressées peuvent s'inscrire pour devenir membres M-Vest. La présentation de la conférence ThinkEquity sera accessible via webcast.
Clene Inc. (Nasdaq: CLNN), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Verbesserung der mitochondrialen Gesundheit und den Schutz der neuronalen Funktion zur Behandlung neurologischer Krankheiten wie ALS und MS konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im Oktober 2024 angekündigt.
Das Unternehmen wird vom 15. bis 17. Oktober am 2024 Maxim Healthcare Virtual Summit teilnehmen, mit einer Präsentation, die für den 15. Oktober um 14:30 Uhr E.T. geplant ist. Clene wird auch am The ThinkEquity Conference 2024 am 30. Oktober in New York City teilnehmen und um 15:30 Uhr E.T. präsentieren.
Beide Veranstaltungen werden Präsentationen und individuelle Meetings beinhalten. Für den Maxim Healthcare Virtual Summit können interessierte Parteien sich anmelden, um M-Vest-Mitglieder zu werden. Die Präsentation der ThinkEquity Conference wird über einen Webcast zugänglich sein.
- None.
- None.
SALT LAKE CITY, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the following investor conferences in October.
2024 Maxim Healthcare Virtual Summit
Date: October 15-17, 2024
Location: Virtual
Presentation: October 15, 2024, at 2:30 p.m. E.T.
Format: Fireside Presentation and 1x1 meetings
Attendance: Sign up to become an M-Vest member
The ThinkEquity Conference 2024
Dates: October 30, 2024
Location: New York, New York, Mandarin Oriental Hotel
Presentation: October 30, 2024, at 3:30 p.m. E.T.
Format: Presentation and 1x1 meetings
Webcast Link: https://wsw.com/webcast/tep25/clnn/1673136
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
Contacts:
| Media Contact Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC Ignacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310 | Investor Contact Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com 617-283-2856 |
FAQ
What investor conferences will Clene Inc. (CLNN) attend in October 2024?
When is Clene's (CLNN) presentation at the 2024 Maxim Healthcare Virtual Summit?
Where can I watch Clene's (CLNN) presentation at The ThinkEquity Conference 2024?
What neurological diseases does Clene Inc. (CLNN) focus on treating?
